Recurrent Ovarian Cancer: When and How to Treat
Recurrent Ovarian Cancer: When and How to Treat
复制标题
DOI：
10.1007/s11912-011-0199-3
复制
发表时间：
2011-12-01
影响因子：
4.7
通讯作者：
Rustin, Gordon
中科院分区：
文献类型：
--
作者：
Hall, Marcia;Rustin, Gordon
尽管不断努力改善卵巢癌的初级治疗，但大多数患者最终会出现复发性疾病。在MRC/EORTC CA 125监测试验的介绍之后，复发的检测和早期系统治疗的益处现在受到怀疑。二次肿瘤细胞减灭术对生存率的影响需要更多的研究。抗血管生成剂和其他生物制剂（如PARP抑制剂）的作用对于患者来说变得越来越重要，作为更常规的细胞毒性治疗的补充或替代。在复发性卵巢癌的治疗和这种干预的时机方面都有很多选择。本文不仅探讨了如何治疗这些患者，但也有争议的问题，何时治疗。教育和参与患者在决定他们的治疗方案是至关重要的。
Notwithstanding continuing efforts to improve the primary treatment for ovarian cancer, most patients will ultimately develop recurrent disease. The benefits of detection and early systemic treatment of recurrence are now in doubt following the presentation of the MRC/EORTC CA125 surveillance trial. The impact of secondary cytoreductive surgery on survival requires more investigation. The role of antiangiogenic and other biological agents such as PARP inhibitors is becoming increasingly important for patients as an addition or alternative to the more conventional cytotoxic therapies available. Uncertainties and choices abound both in the treatment of recurrent ovarian cancer and the timing of such interventions. This article not only explores how to treat these patients but also the controversial issue of when to treat. Educating and involving the patient in decisions about their treatment options is of paramount importance.